References
[1] Jenny, N. S., French, B., Arnold, A. M., Strotmeyer, E. S., Cushman, M., Chaves, P. H. (2012). Long-term assessment of inflammation and healthaging in late life: the Cardiovascular Health Study All Stars. J Gerontol A Biol Sci Med Sci., 2012 Sep, 67(9): 970-6. doi: 10.1093/gerona/glr261. Epub 2012 Feb.
[2] Gomez, C. R., Boehmer, E. D., Kovacs, E. J. (2005). The aging innate immune system. Curr Opin Immunol., 2005, 17: 457.
[3] Fernández-Ballesteros, R., Marie Robine, J., Walker, A., and Kalache, A. Active Aging: A Global goal. Hindawi. https://doi.org/10.1155/2013/298012.
[4] Cevenini, E., Monti, D., Franceschi, C. (2013). Inflamm-ageing. Curr Opin Clin Nutr Metab Care, 2013, 16: 14-20. doi: 10.1097/MCO.0b013e32835ada13.
[5] Minciullo, P. L., Catalano, A., Mandraffino, G., Casciaro, M., Crucitti, A., Maltese, G., et al. (2016). Inflammaging and anti-inflammaging: the role of cytokines in extreme longevity. Arch Immunol Ther Exp (Warsz), 2016, 64: 111-26. doi: 10.1007/s00005-015-0377-3.
[6] Mohammed, S. F., Borlaug, B. A., Roger, V. L., Mirzoyev, S. A., Rodeheffer, R. J. (2012). Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study. Circ Heart Fail, 2012 Nov, 5(6): 710-9. doi: :10.1161/CIRCHEARTFAILURE.112.968594.
[7] Little, W. C., Zile, M. R. (2012). HFpEF: Cardiovascular abnormalities not just comorbidities. Circ Heart Fail, 2012, 5: 6696-6671.
[8] Lopez-Candales, А., Hernández Burgos, P., Hernandez-Suarez, D. (2017). Linking Chronic Inflammation with Cardiovascular Disease: From Normal Aging to the Metabolic Syndrome. J Nat Sci., 2017 Apr, 3(4): e341. doi.org/10.1016/j.jfma.2017.02.002.
[9] Guarner, V., Esther Rubio-Ruiz, M. (2014). Low-Grade Systemic Inflammation Connects Aging, Metabolic Syndrome and Cardiovascular Disease. Interdiscipl Top Gerontol. Basel, Karger, 2014, vol. 40, pp. 99-106. DOI: 10.1159/000364934.
[10] Fang, L., Ellims, A. H., Beale, A. L., Taylor, A. J., Murphy, A., Dart, A. M. (2017). Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy. Am J Transl Res., 2017 Nov 15, 9(11): 5063-5073. Collection 2017.
[11] Apovian, C. M., Gokce, N. (2012). Obesity and cardiovascular disease. Circulation, 2012, 125: 1178-82 doi: 10.1161/CIRCULATIONAHA.111.022541.
[12] N. R. S. Pivetta, J. C. S. Marincolo, A. L. Neri, I. Aprahamian, M. S. Yassuda. (2019). Multimorbidity, frailty and functional disability in octogenarians: A structural equation analysis of relationship. https://doi.org/10.1016/j.archger.2019.
[13] Phan, T. T. and Frenneaux, M. (2010). The pathophysiology of diastolic heart failure. Biology reports, 2010, 2; 16-20, Feb 24. doi: 10.3410/B2-16.
[14] Paulus, J. W., Tschöpe, C. (2013). A Novel Paradigm for Heart Failure With Preserved Ejection Fraction: Comorbidities Drive Myocardial Dysfunction and Remodeling Through Coronary Microvascular Endothelial Inflammation. doi.org/10.1016/j.jacc.2013.02.092.
[15] Lam, C. S., Roger, V. L., Roden Heffer, R. J., et al. (2007). Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted Country, Minnesota, Circulation, 2007, 115: 1982-990.
[16] Edelmann, F., at al. (2011). Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clinical Research in cardiology, 100, 755-764/2011.
[17] Streng, K. W., Nauta, J., et al. (2016). Non- cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. https//doi.org/10.2016.
[18] Zoppini, G., et al. (2018). The E/e' ratio difference between subjects with type 2 diabetes and controls. A meta-analysis of clinical studies. PLoS One, 2018.
[19] Masiha, S., Sundström, J., Lind, L. (2013). Inflammatory markers are associated with left ventricular hypertrophy and diastolic dysfunction in a population-based sample of elderly men and women. J Hum Hypertens, 2013 Jan, 27(1): 13-7. https://doi.org/10.1038/jhh.2011.113.
[20] Ueland, L., Vinge, T., Elif, E., Finsen, A., Aukrust, P. (2012). Inflammatory Cytokines in Heart Failure: Mediators and Markers. Cardiology, 2012, 122: 23-35.
[21] Giovannini, S., Onder, G., Liperoti, R., Russo, A., Carter, C., Capoluongo, E., et al. (2011). Interleukin-6, C-reactive protein, and tumor necrosis factor-α as predictors of mortality in frail, community-living elderly individuals. J Am Geriatr Soc., 2011, 59: 1679-85. doi: 10.1111/j.1532-5415.
[22] Cesari, M., Onder, G., Zamboni, V., Capoluongo, E., Russo, A., Bernabei, R., et al. (2009). C-reactive protein and lipid parameters in older persons aged 80 years and older. J Nutr Health Aging, 2009, 13: 587-93. doi: 10.1007/s12603-009-0168-9.
[23] Ozuğuz, U., Ergün, G., Işık, S., Gökay, F., Tütüncü, Y., Akbaba, G., Berker, D., Güler, S. Association between C-reactive protein, carotid intima-media thickness and P-wave dispersion in obese premenopausal women: an observational study. Original Investigation Özgün Araşt›rma.
[24] Meléndez, G. C., McLarty, J. L., Levick, S. P., Du, Y., Janicki, J. S., Brower, G. L. (2010). Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension, 2010 Aug, 56(2): 225-31. doi: 10.1161/HYPERTENSIONAHA.109.148635. Epub 2010 Jul 6.
[25] Dinh, W., Füth, R., Nickl, W., Krahn, T., Ellinghaus, P., Scheffold, T., et al. (2009). Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. Cardiovasc Diabetol, 2009 Nov 12, 8: 58. https://doi.org/10.1186/1475-2840-8-58.
[26] Tang, Y., Fung, E., Xu, A., Lan, H. Y. (2017). C-reactive protein and ageing. Clin Exp Pharmacol Physiol., 2017 Dec, 44 Suppl 1: 9-14. doi: 10.1111/1440-1681.12758.
[27] Ahmadi-Abhari, S., Luben, R. N., Wareham, N. J., Khaw, K. T. (2013). Distribution and determinants of C-reactive protein in the older adult population: European Prospective Investigation into Cancer-Norfolk study. Eur J Clin Invest., 2013, 43: 899-911. doi: 10.1111/eci.12116.
[28] Abhayaratna, W. P., Marwick, T. H., Smith, W. T., Becker, N. G. (2006). Characteristics of left ventricular diastolic dysfunction in the community: an echocardiographic survey. Heart, 2006, 92: 1259-64.
[29] Gottdiener, J. S., Kitzman, D. W., Aurigemma, G. P., et al. (2006). Left atrial volume, geometry, and function in systolic and diastolic heart failure of persons > 65 years of age (the cardiovascular health study). Am J Cardiol, 2006, 97: 83-9.
[30] Cioffi, G., Mureddu, G. F., Stefenelli, C. (2006). Infuence of age on the relationship between left atrial performance and left ventricular systolic function in systemic arterial hypertension. Exp Clin Cardiol., 2006, 11: 305-10.
[31] Hristovski, Z., Zafirovska, P., Projevska-Donegati, D., Georgievska-Ismailj, L. J. (2013). Assesment of diastolic dysfunction in patients with diabetic cardiomyopathy and preserved systolic left ventricular function. Physioacta, 2013, 7: 9-22.
[32] Veterovska Miljkovic, L., Spiroska, V. (2015). Heart Failure with Preserved Ejection Fraction- Concept, pathophisiology, Diagnosis and Challenges for Treatment. Open Access Macedonian Journal of Medical Sciences, 2015: 3(3): 521-527.
[33] Deepak Y. Kamath, Denis Xavier, Alben Sigamani. (2015). High sensitivity C-reactive protein (hsCRP) & cardiovascular disease: An Indian perspective. Indian J Med Res., 2015 Sep, 142(3): 261-268. doi: 10.4103/0971-5916.166582.
[34] Windgassen, E. B., Funtowicz, L., Lunsford, T. N., Harris, L. A., Mulvagh, S. L. (2011). C-Reactive Protein and High-Sensitivity C-Reactive protein: an Update for Clinicians. Postgrad Med., 2011 Jan, 123(1): 114-9.
[35] Vaucher, J., Marques-Vidal, P., Waeber, G., Vollenweider, P. (2014). Cytokines and hs-CRP levels in individuals treated with low-dose aspirin for cardiovascular prevention: a population-based study (CoLaus Study). Cytokine, 2014, 66: 95-100. doi: 10.1016/j.cyto.2014.01.003.
[36] Franceschi, C., Capri, M., Monti, D., et al. (2007). Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev., 2007, 128(1): 92-105.
[37] Nadrowski, P., Chudek, J., Skrzypek, M., Puzianowska-Kuźnicka, M., Mossakowska, M., Więcek, A., et al. (2016). Associa-tions between cardiovascular disease risk factors and IL-6 and hsCRP levels in the elderly. Exp Gerontol, 2016 Dec 1, 85: 112-117. https://doi.org/10.1016/j.exger.2016.10.001.
[38] Lang, R. M., Badano, L. P., Mor-Avi, V., Afilalo, J., Armstrong, A., Ernande, L., et al. (2015). Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr, 2015 Jan, 28(1): 1-39.e14. https://doi.org/ 10.1016/ j.echo.2014.10.003.
[39] Nagueh, S. F., Smiseth, O. A., Appleton, C. P., Byrd, B. F. 3rd, Dokainish, H., Edvardsen, T., et al.; Houston, Texas; Oslo, Norway; Phoenix, Arizona; Nashville, Tennessee; Hamilton, Ontario, Canada; Uppsala, Sweden, et al. (2016). Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur HeartJCardiovascImaging, 2016 Dec, 17(12): 1321-1360. https://doi.org/10.1093/ehjci/jew082.
[40] Ridker, P. From CRP to IL-6 to IL-1: Moving Upstream To Identify Novel Targets for Atheroprotection. doi: 10.1161/CIRCRESAHA.115.306656.